BG100991A - Методи за индуциране на т-клетъчна толерантност към тъканна или органна присадка - Google Patents

Методи за индуциране на т-клетъчна толерантност към тъканна или органна присадка

Info

Publication number
BG100991A
BG100991A BG100991A BG10099196A BG100991A BG 100991 A BG100991 A BG 100991A BG 100991 A BG100991 A BG 100991A BG 10099196 A BG10099196 A BG 10099196A BG 100991 A BG100991 A BG 100991A
Authority
BG
Bulgaria
Prior art keywords
cell
methods
tissue
xenogenic
recepient
Prior art date
Application number
BG100991A
Other languages
English (en)
Other versions
BG62121B1 (bg
Inventor
Randolph Noelle
Fiona Durie
David Parker
Michael Appel
Nancy Philips
John Mordes
Dale Grenier
Aldo Rossini
Original Assignee
Trustees Of Dartmouth College
University Of Massachusetts Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Dartmouth College, University Of Massachusetts Medical Center filed Critical Trustees Of Dartmouth College
Publication of BG100991A publication Critical patent/BG100991A/bg
Publication of BG62121B1 publication Critical patent/BG62121B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

Изобретението се отнася до методи за индуциране на Т-клетъчна толерантност към тъканна или органна присадка в реципиент на трансплантат. Методите включват въвеждане в субект на алогенна или ксеногенна клетка, която експресира донорни антигени и има върху клетъчната повърхност лиганд, взаимодействащс рецептор от повърхността на реципиентна Т-клетка, опосредстваща контактзависимата помощна (хелперна) ефекторна функция, и на антагонист на рецептора, който инхибира взаимодействието на лиганда с рецептора. В предпочитано приложение алогенната или ксеногенна клетка е В-клетка, за предпочитане В-клетка в покой, а молекулата от повърхността на Т-клетката, която опосредства контактзависимата помощна функция, е др39. Предпочитан антагонист на др39 е анти-др39 антитяло. Алогенната или ксеногенна клетка и антагонистът на др39 като правило се въвеждат в реципиента на трансплантата преди трансплантацията на тъканта или органа. Методите съгласно изобретението могат да се използват за индуциране на Т-клетъчна толерантност към трансплантати като черен дроб, бъбрек, сърце, бял дроб, кожа, мускул, нервна тъкан, стомах или черво. Изобретението се отнася и до метод за лечение на диабет, включващ въвеждане в субект на алогенни или ксеногенни клетки, експресиращи донорни антигени, на антагонист на др39 и на панкреатични островчета.
BG100991A 1994-04-25 1996-11-19 Методи за индуциране на т-клетъчна толерантност към тъканнаили органна присадка BG62121B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/234,987 US5683693A (en) 1994-04-25 1994-04-25 Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
PCT/US1995/004832 WO1995028957A2 (en) 1994-04-25 1995-04-25 Methods for inducing t cell tolerance to a tissue or organ graft

Publications (2)

Publication Number Publication Date
BG100991A true BG100991A (bg) 1998-01-30
BG62121B1 BG62121B1 (bg) 1999-03-31

Family

ID=22883593

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100991A BG62121B1 (bg) 1994-04-25 1996-11-19 Методи за индуциране на т-клетъчна толерантност към тъканнаили органна присадка

Country Status (34)

Country Link
US (4) US5683693A (bg)
EP (2) EP1530973A3 (bg)
JP (1) JP2974415B2 (bg)
KR (1) KR100468330B1 (bg)
CN (1) CN1134266C (bg)
AP (1) AP764A (bg)
AT (1) ATE288281T1 (bg)
AU (1) AU710925B2 (bg)
BG (1) BG62121B1 (bg)
BR (1) BR9507509A (bg)
CA (1) CA2188672A1 (bg)
CZ (1) CZ291266B6 (bg)
DE (1) DE69533984T2 (bg)
DK (1) DK0757557T3 (bg)
EE (1) EE03516B1 (bg)
ES (1) ES2237757T3 (bg)
FI (1) FI118792B (bg)
GE (1) GEP20022648B (bg)
HU (1) HU221752B1 (bg)
IS (1) IS2118B (bg)
LT (1) LT4309B (bg)
LV (1) LV11785B (bg)
MD (1) MD1444B2 (bg)
NO (2) NO319787B1 (bg)
NZ (1) NZ284905A (bg)
OA (1) OA10591A (bg)
PL (1) PL180031B1 (bg)
PT (1) PT757557E (bg)
RO (1) RO114743B1 (bg)
RU (1) RU2169009C2 (bg)
SI (1) SI9520057A (bg)
SK (1) SK136996A3 (bg)
UA (1) UA44892C2 (bg)
WO (1) WO1995028957A2 (bg)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
IL110855A (en) * 1993-09-02 1999-04-11 Dartmouth College Methods for inducing antigen-specific t cell tolerance
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
WO1998030241A1 (en) * 1997-01-10 1998-07-16 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
EP1754490A3 (en) * 1997-06-20 2010-01-20 Biogen Idec MA Inc. CD 154 blockage therapy for pancreatic islet tissue transplantation in primates
JP2002506446A (ja) * 1997-06-20 2002-02-26 バイオジェン，インコーポレイテッド ランゲルハンス島組織の移植のためのｃｄ１５４遮断治療
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
ATE309808T1 (de) * 1998-07-30 2005-12-15 Univ Minnesota Ex vivo behandlung von allogenen und xenogenen t- zellen mit gp39-antagonisten
US20020199218A1 (en) * 1999-08-19 2002-12-26 Daphne Goring Proline-rich extensin-like receptor kinases
RU2162297C1 (ru) * 1999-11-25 2001-01-27 Камакин Владислав Владимирович Способ индивидуального подбора оптимального питания человека
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
JP2003533488A (ja) 2000-05-12 2003-11-11 ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド 免疫抑制を達成するための組成物および方法
EP1289554A4 (en) * 2000-06-02 2004-05-26 Univ Minnesota IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS
CA2410188A1 (en) * 2000-06-06 2001-12-13 Idec Pharmaceutical Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
EP1372696B1 (en) 2000-07-03 2008-07-23 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2364983A1 (en) * 2000-12-13 2002-06-13 John R. Coleman Nucleic acid molecules and polypeptides for catabolism of abscisic acid
WO2002078743A1 (en) * 2001-02-16 2002-10-10 University Of Rochester Compositions and methods for reducing tranfusion reactions
US7597895B2 (en) * 2001-02-20 2009-10-06 The Governing Council Of The University Of Toronto Signal peptides, nucleic acid molecules and methods for treatment of caries
US7556807B2 (en) 2001-02-20 2009-07-07 Kane Biotech, Inc. Signal peptides, nucleic acid molecules and methods for treatment of caries
HU229680B1 (hu) 2001-05-23 2014-04-28 Bristol Myers Squibb Co Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP1649282A4 (en) * 2003-07-07 2007-08-29 Webb Waring Inst PROCESS FOR PREDICTING THE DEVELOPMENT OF AUTOIMMUNE DISEASES AND TREATMENT THEREOF
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1795587A1 (en) * 2005-12-07 2007-06-13 Schuler, Gerold, Prof. Dr. Method for the direct culture of dendritic cells without a preceding centrifugation step
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
FR2934140B1 (fr) * 2008-07-25 2010-09-03 Seb Sa Couvercle d'appareil electromenager de cuisson comportant un sous-ensemble de filtration
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
CN113699116A (zh) 2014-12-10 2021-11-26 明尼苏达大学董事会 用于治疗疾病的遗传修饰的细胞、组织和器官
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69021456T2 (de) * 1989-05-23 1996-02-15 Otsuka Pharma Co Ltd Monoklonale Antikörper gegen aktivierte endotheliale Zellen.
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
DK0897983T3 (da) * 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
MX9306682A (es) * 1992-10-30 1994-04-29 Bristol Myers Squibb Co Ligandos del receptor de la matriz extracelular, que modulan la funcion de los leucocitos.
IL110855A (en) * 1993-09-02 1999-04-11 Dartmouth College Methods for inducing antigen-specific t cell tolerance
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40

Also Published As

Publication number Publication date
HUT76091A (en) 1997-06-30
NO319787B1 (no) 2005-09-12
UA44892C2 (uk) 2002-03-15
BG62121B1 (bg) 1999-03-31
RO114743B1 (ro) 1999-07-30
WO1995028957A2 (en) 1995-11-02
NO20051182L (no) 1996-12-23
CZ291266B6 (cs) 2003-01-15
CN1150760A (zh) 1997-05-28
EP0757557B1 (en) 2005-02-02
BR9507509A (pt) 1997-02-02
MD970009A (en) 1999-01-31
WO1995028957A3 (en) 1995-11-23
DE69533984D1 (de) 2005-03-10
US7501124B2 (en) 2009-03-10
ES2237757T3 (es) 2005-08-01
AU2358595A (en) 1995-11-16
CZ312596A3 (en) 1997-03-12
MD1444B2 (ro) 2000-04-30
IS4378A (is) 1996-10-22
FI964272A (fi) 1996-12-19
AP9600906A0 (en) 1997-01-31
GEP20022648B (en) 2002-03-25
PL180031B1 (pl) 2000-12-29
CA2188672A1 (en) 1995-11-02
NZ284905A (en) 2004-10-29
IS2118B (is) 2006-06-15
HU221752B1 (hu) 2002-12-28
FI964272A0 (fi) 1996-10-23
US20050152897A1 (en) 2005-07-14
FI118792B (fi) 2008-03-31
US5902585A (en) 1999-05-11
CN1134266C (zh) 2004-01-14
PL317022A1 (en) 1997-03-03
LT96165A (en) 1997-11-25
AU710925B2 (en) 1999-09-30
SK136996A3 (en) 1999-01-11
JPH09512271A (ja) 1997-12-09
RU2169009C2 (ru) 2001-06-20
SI9520057A (sl) 1998-06-30
JP2974415B2 (ja) 1999-11-10
EP1530973A2 (en) 2005-05-18
LV11785A (lv) 1997-06-20
US6375950B1 (en) 2002-04-23
EE9600162A (et) 1997-06-16
EP1530973A3 (en) 2006-12-27
HU9602924D0 (en) 1996-12-30
ATE288281T1 (de) 2005-02-15
LT4309B (lt) 1998-03-25
LV11785B (en) 1998-02-20
US5683693A (en) 1997-11-04
EP0757557A1 (en) 1997-02-12
DE69533984T2 (de) 2006-04-27
NO964440D0 (no) 1996-10-18
KR100468330B1 (ko) 2005-12-30
NO964440L (no) 1996-12-23
OA10591A (en) 2002-07-15
DK0757557T3 (da) 2005-05-23
EE03516B1 (et) 2001-10-15
AP764A (en) 1999-09-16
PT757557E (pt) 2005-05-31

Similar Documents

Publication Publication Date Title
BG100991A (bg) Методи за индуциране на т-клетъчна толерантност към тъканна или органна присадка
ATE88097T1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
GR3036778T3 (en) -i(IN VITRO) CORNEA EQUIVALENT MODEL.
DE69827001D1 (de) Gewebedezellularization
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
DE69739833D1 (de) Schrittmacher zur erhöhung des herzzeitvolumens
WO1998020932A3 (en) Conditioning for allogeneic stem cell transplantation
DE69637730D1 (de) Verfahren zur in vito vorbehandlung von myoblasten vor deren transplantation
EP0815204A4 (en) METHOD OF TREATING TUMORS
HK1212885A1 (zh) 細胞懸液製備裝置
HU9403139D0 (en) Method and apparatus for cosmetical treatment of the human body through removal of adipose masses
PL325897A1 (en) Patient-specific immunoadsorbents for extracorporeal apherresis and method of obtaining them
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
WO2003084386A3 (en) Methods for ultrasonic imaging and treating diseased tissues
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
WO2006038211A3 (en) Disease treatment via developing non-syngeneic graft transplantation
MX9605051A (es) Metodos para inducir la tolerancia de celulas t a un injerto u organo.
WO2001000679A3 (en) Methods for inducing t cell non-responsiveness to a tissue or organ graft
Hilkert Naming grace
Costanzo Heart transplantation: Editorial overview
ATE253378T1 (de) Xenogene transplantation
UA69988A (en) Method for treating complicated choledocholithiasis
UA32295A (uk) Спосіб лікування порушень фертильності у хворих на цукровий діабет